Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients

Table 2 Podoplanin expression in esophageal cancer squamous cell carcinoma of the esophagus vs adenocarcinoma of the esophagus

	Total		ESCC		EAC
	n	Podoplanin > 5% (HPE, %)	n	Podoplanin > 5% (HPE, %)	n	Podoplanin > 5% (HPE, %)
Total study cohort	195	13	90	26	105	2
Gender
Male	155	10	61	23	94	1
Female	40	25	29	32	11	9
Therapy
Surgery only	89	19	32	50	57	2
RTx/CTx + surgery	106	7	58	11	48	2
T-category
pT2	30	3	6	17	24	0
cT/pT3	165	14	84	27	81	3
Endoscopic biopsy	104	7	58	38	46	2

Biopsies and resected specimen of patients with adeno- and squamous cell carcinoma, scoring by immunohistochemically stained D2-40. HPE: High podoplanin expression; EAC: Adenocarcinoma of the esophagus; ESCC: Squamous cell carcinoma of the esophagus; pT: Pathologic tumor; cT: Clinical tumor category; RTx/CTx: Neoadjuvant radio-/chemotherapy.